As I was going through the 2015 JSM Online Program, I was struck by the number of sessions related to personalized medicine (perhaps confirmation bias from the new ASA one-pager to promote statistics and statisticians in the Precision Medicine Initiative.) Below are just some I could identify by using the great search feature of the online program but I hope you'll spend more time using it to identify precision medicine talks. I also hope you'll let me know of any I missed.
The first list are sessions where "Personalized" appears in the title and includes an Introductory Overview Lecture by Erica Moodie, Michael Kosorok, and Eric Laber; the Medallion Lecture by Michael Kosorok; and the Wald Lectures by Susan Murphy.
Below the first list are talk titled with "personalized" in the abstract. I've also included talks with key words associated with or related to precision medicine (I did not de-duplicate these):
See also these keyword searches: biomarker (87 results); dynamic treatment regime (16 results); next generation sequencing (8 results). And feel free to suggest other keywords for precision medicine to me.
See also, Big Data Sessions at the 2015 Joint Statistical Meetings, and coming soon, Neuroscience talks at JSM.
I'm also aware of several statistics-intensive sessions on the topic at other conferences. For example:
See other ASA Science Policy blog entries. For ASA science policy updates, follow @ASA_SciPol on Twitter.
Personalized Medicine Sessions
Talks with "Personalized" in the abstract
Monday, 08/10/2015
|
Personalized Plans with Multiple Treatments
Chathura Siriwardhana, University of Louisville; Meng Zhao, Mississippi State University; Somnath Datta, University of Louisville; Karunarathna Kulasekera, University of Louisville
|
Personalized Evaluation of Biomarker Value in Risk Prediction and Treatment Selection: A Cost-Benefit Perspective
Ying Huang, Fred Hutchinson Cancer Research Center; Eric Laber, North Carolina State University
10:35 AM
|
Prognostic and Predictive Values and Statistical Interactions in the Era of Personalized Medicine
Jaya M. Satagopan, Memorial Sloan Kettering Cancer Center; Alexia Iasonos, Memorial Sloan Kettering Cancer Center; Qin Zhou, Memorial Sloan Kettering Cancer Center
11:25 AM
|
Modeling Placebo Response Using Multiple Functional Predictors
Thaddeus Tarpey, Wright State University; Eva Petkova, New York University School of Medicine; R. Todd Ogden, Columbia University; Adam Ciarleglio, New York University; Bei Jiang, Columbia University/New York University
2:05 PM
|
Assessing Instructional Modalities: Individualized Treatment Effects for Personalized Learning
Richard Levine, San Diego State University
3:05 PM
|
Tuesday, 08/11/2015
|
A Novel Method of Subgroup Identification by Using Virtual Twins and GUIDE (VG) for Development of Personalized Medicines
Jia Jia; Qi Tang, AbbVie; Wangang Xie, AbbVie; Richard Rode, AbbVie
|
A Localized Prediction Algorithm for Personalized Trauma Care
Sara Moore; Alan Hubbard, UC Berkeley; Mitchell J. Cohen, UC San Francisco
|
A Localized Prediction Algorithm for Personalized Trauma Care
Sara Moore; Alan Hubbard, UC Berkeley; Mitchell J. Cohen, UC San Francisco
9:05 AM
|
Some Statistical Method in Bridging Efficacy Studies for Companion Diagnostic Tests
Xiao-Hua Zhou, University of Washington
10:35 AM
|
Discovery of Principles of Nature from Matrix and Tensor Modeling of Large-Scale Molecular Biological Data
Orly Alter, University of Utah
10:35 AM
|
Nonparametric Generated Effect Modifiers for Placebo Response
Eva Petkova, New York University School of Medicine; Thaddeus Tarpey, Wright State University; Adam Ciarleglio, New York University; Bei Jiang, New York University School of Medicine; R. Todd Ogden, Columbia University; Zhe Su, New York University
10:35 AM
|
There's Personalized Medicine. Why Not Personalized Inference?
Xiao-Li Meng, Harvard University; Keli Liu, Stanford University
11:00 AM
|
Medallion Lecture: Recent Developments in Machine Learning for Personalized Medicine
Michael Kosorok, The University of North Carolina at Chapel Hill
2:05 PM
|
Evaluation of Biomarkers for Treatment Selection Using Individual Participant Data Meta-Analysis
Chaeryon Kang, University of Pittsburgh; Holly Janes, Fred Hutchinson Cancer Research Center
2:05 PM
|
Adaptive Enrichment Designs with Population Selection Based on an Ordinal Biomarker
Michael Rosenblum, Johns Hopkins Bloomberg School of Public Health; Yu Du, The Johns Hopkins University; Aaron Fisher, The Johns Hopkins University; Tianchen Qian
2:05 PM
|
Subgroup Mixable Inference with Time-to-Event Outcomes in Personalized Medicine Development
Ying Ding, University of Pittsburgh
2:50 PM
|
Designing a Confirmatory Trial with a Continuous Biomarker Endpoint and an Undetermined Threshold Tested at Both the Interim and Final
Adarsh Joshi, Gilead Sciences; Jenny Zhang, Gilead Sciences; Nusrat Rabbee, UC Berkeley; Liang Fang, Gilead Sciences
3:05 PM
|
Sequential Decision-Making and Personalized Treatment: The Future Is Now!
Susan A. Murphy, University of Michigan
4:05 PM
|
Wednesday, 08/12/2015
|
Decision-Making in Post Clinical Trials
Heping Zhang, Yale University
9:00 AM
|
Bias Correction in Subgroup Analysis with Survival Outcomes
Lu Tian, Stanford University; LJ Wei, Harvard University; Fei Jiang, Harvard University
9:25 AM
|
Personalized Predictions Using Exogenous Covariates
Jie Fan; J. Sunil Rao, University of Miami
9:50 AM
|
Issues That Arise During the FDA Review of Applications Containing Patient and Clinician Reported Outcomes
Laura Lee Johnson, FDA; Scott Komo, FDA/CDER/OTS/OB/DBIV; Thomas Birkner, FDA/CDER/OTS/OB/DBI; LaRee Tracy, FDA/CDER/OTS/OB/DBIV; Stephen Wilson, FDA/CDER/OTS/OB/DBIII; Wen-Hung Chen, FDA/CDER/OND/SEALD; Martin Ho, FDA/CDRH
10:35 AM
|
Sequential Designs for Individualized Dosing in Phase I Cancer Clinical Trials
Xuezhou Mao, Sanofi-Aventis U.S.; Ken Cheung, Columbia University
11:25 AM
|
Logical Inference on Efficacy in Subgroups and Their Combinations in Personalized Medicine
Jason Hsu, The Ohio State University
11:35 AM
|
Composite Score-Based Decision Rule as a Predictive Signature for Patient Subgroup Identification
Xin Huang; Yan Sun, AbbVie; Lu Tian, Stanford University; Viswanath Devanarayan, AbbVie
11:50 AM
|
Learning Optimal Personalized Treatment Rules Under Risk Constraint
Yuanjia Wang, Columbia University; Haoda Fu, Eli Lilly and Company; Donglin Zeng, The University of North Carolina
2:05 PM
|
Algorithms for Prediction and Subgroup Formation in Personalized Medical Decision-Making
Kelci Miclaus, SAS Institute; Richard Zink, SAS Institute; Russ C. Wolfinger, SAS Institute
2:05 PM
|
Thursday, 08/13/2015
|
Brain Imaging and Personalized Medicine in Psychiatry
R. Todd Ogden, Columbia University; Adam Ciarleglio, New York University; Bei Jiang, Columbia University/New York University; Eva Petkova, New York University School of Medicine; Thaddeus Tarpey, Wright State University
9:00 AM
|
A Unified Family of Covariate-Adjusted Response-Adaptive Designs Based on Efficiency and Ethics
Jianhua Hu, MD Anderson Cancer Center; Hongjian Zhu, The University of Texas School of Public Health; Feifang Hu, The George Washington University
9:35 AM
|
Interpretable Treatment Regimes
Yichi Zhang, North Carolina State University; Eric Laber, North Carolina State University; Anastasios Tsiatis, North Carolina State University ; Marie Davidian, North Carolina State University
11:50 AM |
Sessions or Talks with "Subgroup"
Monday, 08/10/2015
|
A Comparison of Alternative Approaches to Analyzing Subgroup Differences in Survival After AIDS Diagnosis When the Proportional Hazards Assumption Does Not Hold
Felicia Hardnett, CDC; Qian An, CDC; Xinjian Zhang, CDC
|
Dunn Index Bootstrap (DIBS): A Procedure to Empirically Select a Cluster Analysis Method That Identifies Biologically and Clinically Relevant Molecular Subgroups
Iwona Pawlikowska, St. Jude Children's Research Hospital; Zhifa Liu, St. Jude Children's Research Hospital; Arzu Onar-Thomas, St. Jude Children's Research Hospital; Stan Pounds, St. Jude Children's Research Hospital
|
Identifying a Patient Subgroup with Differential Treatment Benefit
David Prince, University of Washington; Susanne May, University of Washington; Scott Emerson, University of Washington; Michael LeBlanc, Fred Hutchinson Cancer Research Center; Erika Thommes, University of Washington
9:50 AM
|
Subgroup Analysis: Issues in FDA-Reviewed Clinical Trials
Kathleen Fritsch, FDA
10:35 AM
|
A Comparison of Alternative Approaches to Analyzing Subgroup Differences in Survival After AIDS Diagnosis When the Proportional Hazards Assumption Does Not Hold
Felicia Hardnett, CDC; Qian An, CDC; Xinjian Zhang, CDC
10:55 AM
|
Visualization Tools for Subgroup Analysis: Are We Using Them to Their Optimal Capacity?
Vipin Arora, Eli Lilly and Company
10:55 AM
|
Dunn Index Bootstrap (DIBS): A Procedure to Empirically Select a Cluster Analysis Method That Identifies Biologically and Clinically Relevant Molecular Subgroups
Iwona Pawlikowska, St. Jude Children's Research Hospital; Zhifa Liu, St. Jude Children's Research Hospital; Arzu Onar-Thomas, St. Jude Children's Research Hospital; Stan Pounds, St. Jude Children's Research Hospital
11:15 AM
|
Casting the Bones: The Worth and Potential Worthlessness of Subgroup Analyses
Kevin Buhr, University of Wisconsin - Madison
11:15 AM
|
Subgroup Analysis Findings of Safety with No Statistical Power: What Do These Really Mean?
Melvin Munsaka, Takeda Development Center Americas, Inc.
11:35 AM
|
Subgroup-Based Adaptive (SUBA) Designs for Sequential, Multiple Assignment, Randomized Trials
Yanxun Xu, The University of Texas at Austin; Peter Mueller, The University of Texas at Austin; Peter F. Thall, MD Anderson Cancer Center
11:50 AM
|
Tuesday, 08/11/2015
|
Regularized Outcome Weighted Subgroup Identification for Differential Treatment Effects
Yaoyao Xu, AbbVie; Menggang Yu, University of Wisconsin - Madison; Yingqi Zhao, University of Wisconsin - Madison; Quefeng Li, Princeton University; Sijian Wang, University of Wisconsin - Madison; Jun Shao, University of Wisconsin - Madison
|
A Novel Method of Subgroup Identification by Using Virtual Twins and GUIDE (VG) for Development of Personalized Medicines
Jia Jia; Qi Tang, AbbVie; Wangang Xie, AbbVie; Richard Rode, AbbVie
|
Reducing Alpha Adjustment When Tests Are Structurally Correlated
Jonathan Siegel, Bayer HealthCare Pharmaceuticals
|
Generalized Error Rates for Subgroup Analyses
Xiaolei Xun, Novartis; Frank Bretz, Novartis; Willi Maurer, Novartis
|
Closing the Research Practice Gap in Personalized Medicine
Eric Laber, North Carolina State University
|
Do Subgroup Analyses Harm? Usually Not. Are They Helpful? It Depends. A Regulatory and Practical Review
Christoph Muysers, Bayer HealthCare
8:35 AM
|
Multiple Testing in Clinical Trials: Some New Applications
Yunzhi Lin, AbbVie; Kefei Zhou, Amgen; Jeetu Ganju, Hyperion Therapeutics
8:35 AM
|
Common Practices in Industry for Subgroups Identification and Analysis in Clinical Trials
Cristiana Mayer, Janssen R&D/Johnson & Johnson
8:55 AM
|
Many Faces of Subgroup Analysis in Clinical Drug Development
Ilya Lipkovich, Quintiles; Alex Dmitrienko, Quintiles
9:15 AM
|
Multiplicity and Subgroups in Benefit-Risk Assessment
Jonathan Norton
9:35 AM
|
A Bayesian Credible Subgroups Approach to Identifying Patient Subgroups with Positive Treatment Effects
Patrick M. Schnell, University of Minnesota; Qi Tang, AbbVie; Walt Offen, AbbVie; Bradley P. Carlin, University of Minnesota
2:05 PM
|
Subgroup Mixable Inference with Time-to-Event Outcomes in Personalized Medicine Development
Ying Ding, University of Pittsburgh
2:50 PM
|
Designing a Confirmatory Trial with a Continuous Biomarker Endpoint and an Undetermined Threshold Tested at Both the Interim and Final
Adarsh Joshi, Gilead Sciences; Jenny Zhang, Gilead Sciences; Nusrat Rabbee, UC Berkeley; Liang Fang, Gilead Sciences
3:05 PM
|
Change-Plane Analysis for Subgroup Identification and Sample Size Calculation
Ailin Fan, North Carolina State University; Wenbin Lu, North Carolina State University; Rui Song, North Carolina State University
3:20 PM
|
Wednesday, 08/12/2015
|
Incorporating Historical Data in Bayesian Phase I Trial Design: Evaluating the Similarity in Dose-Toxicity Relationship Between Subgroups
Kentaro Takeda, Astellas; Satoshi Morita, Kyoto University Graduate School of Medicine
9:05 AM
|
Bias Correction in Subgroup Analysis with Survival Outcomes
Lu Tian, Stanford University; LJ Wei, Harvard University; Fei Jiang, Harvard University
9:25 AM
|
Logical Inference on Efficacy in Subgroups and Their Combinations in Personalized Medicine
Jason Hsu, The Ohio State University
11:35 AM
|
Composite Score-Based Decision Rule as a Predictive Signature for Patient Subgroup Identification
Xin Huang; Yan Sun, AbbVie; Lu Tian, Stanford University; Viswanath Devanarayan, AbbVie
11:50 AM
|
Thresholding of a Continuous Biomarker Based on a New Concept That Correctly Infers Efficacy in the Target Subgroup
Yi Liu; Jason Hsu, The Ohio State University; Szu-Yu Tang, Ventana Medical Systems, Inc.
11:55 AM
|
Algorithms for Prediction and Subgroup Formation in Personalized Medical Decision-Making
Kelci Miclaus, SAS Institute; Richard Zink, SAS Institute; Russ C. Wolfinger, SAS Institute
2:05 PM
|
Basket Trial Using Bayesian Hierarchical Models
Zijiang Yang
2:20 PM
|
Generalization of Health Effects from Subgroups to Study Populations of Interest
Amber J. Hackstadt, Social & Scientific Systems; Matthew D. Curry, Social & Scientific Systems; Lawrence S. Engel, The University of North Carolina at Chapel Hill; Richard K. Kwok, National Institute of Environmental Health Sciences; Dale P. Sandler, National Institute of Environmental Health Sciences
3:20 PM
|
Thursday, 08/13/2015
|
A Novel Approach in Subgroup Identification Using a Quantitative Benefit-Risk Index
Ramin Arani, AstraZeneca; Ian Hirsch, AstraZeneca; Jonathan Norton, MedImmune; Christy Chuang-Stein, Pfizer Inc.; Weili He, Merck; Shihua Wen, AbbVie; Qi Jiang, Amgen
8:35 AM
|
Dose-Finding Using Hierarchical Modeling for Multiple Subgroups
Kristen Cunanan, University of Minnesota; Joe Koopmeiners, University of Minnesota
8:55 AM
|
Treatment Response Subgroup Identification Using Penalized Regression Spline and Mixture Models
Hongjie Zhu, Sanofi; Lin Wang, Sanofi; Lynn Wei, Sanofi; Hui Quan, Sanofi
9:05 AM
|
Identify Subset of Patients Benefiting from Treatment for Patients with Liver Cancer
Yihuan Xu, Eli Lilly and Company; Yanzhi Hsu, Eli Lilly and Company; Ling Yang, Eli Lilly and Company
9:15 AM
|
Exchangeability and Nonexchangeability in Subgroup Analysis
Margaret Gamalo-Siebers, FDA/CDER; Ram Tiwari, FDA/CDER/OT/OB
9:35 AM
|
Selection of Multiplicity Adjustment Strategy in Confirmatory Trials with a Targeted Subgroup
Cheng Zheng, Novartis Pharmaceuticals; Zhichao Sun, University of Michigan; Kalyanee Appanna, Novartis Pharmaceuticals; Kaushal Mishra, Novartis Pharmaceuticals; Yong Zhang, Novartis Pharmaceuticals; Feng Tai, Novartis Pharmaceuticals
12:05 PM |
Sessions or Talks with "Genome-Wide"
Monday, 08/10/2015
|
The Correction of Length-Bias in Gene Set Analysis for DNA Methylation Data
Shaoyu Li, The University of North Carolina at Charlotte; Iwona Pawlikowska, St. Jude Children's Research Hospital; Tong Lin, St. Jude Children's Research Hospital
|
Integrative Modeling of Multi-Track Hi-C Data for Genome-Scale Reconstruction of 3D Chromatin Structure
Chenchen Zou, The Jackson Laboratory for Genomic Medicine; Yuping Zhang, University of Connecticut; Zhengqing Ouyang, The Jackson Laboratory for Genomic Medicine
|
Optimal Multiple Testing with Prior Information
Edgar Dobriban, Stanford University; Art Owen, Stanford University; Stuart Kim, Stanford University; Kristen Fortney, Stanford University
8:35 AM
|
Practical Methods for Privacy-Preserving Genome-Wide Association Study Data Sharing
Fei Yu, Carnegie Mellon University; Zhanglong Ji, UC San Diego
9:35 AM
|
Semiparametric Mixed-Model Analysis for Nonlinear Gene-Environment Interactions in Genome-Wide Association Studies
Zijian Huang, UC Riverside; Shujie Ma, UC Riverside
12:05 PM
|
Assessing the Impact of Genotype Imputation on Genome-Wide Meta-Analysis
Elif Acar, University of Manitoba; Emmanuel Omondi, University of Basel
3:05 PM
|
Thursday, 08/13/2015
|
Group Association Test Using Hidden Markov Model
Yichen Cheng, Fred Hutchinson Cancer Research Center; James Y. Dai, Fred Hutchinson Cancer Research Center; Charles Kooperberg, Fred Hutchinson Cancer Research Center
8:35 AM
|
Strategies on Genome-Wide Interaction Analysis Using Case-Parents Data
Zhaoxia Yu, UC Irvine
11:25 AM
|
Model Selection in Genome-Wide Association Studies
Kevin Keys, UCLA; Gary Chen, University of Southern California; Kenneth Lange, UCLA
11:35 AM
|
Annotation Regression of Genome-Wide Association Studies (ARoG) with an Application to Psychiatric Genomics Consortium Data
Sunyoung Shin, University of Wisconsin; Sunduz Keles, University of Wisconsin
12:05 PM |
Talks with the word "Targeted" in the abstract
Sunday, 08/09/2015
|
Position-Specific Artifact Removal for Targeted Next-Generation Sequencing--Based Somatic Mutation Detection
John Kang
4:35 PM
|
Enrichment Design for Targeted Therapy
Bo Yang, AbbVie Pharmaceutical Research & Development; Yijie Zhou, AbbVie; Lanju Zhang, AbbVie; Lu Cui, AbbVie
4:45 PM
|
Regulatory Challenges in Reviewing Targeted Therapy Trial
Kun He, DBV/OB/CDER/FDA; Rajeshwari Sridhara, FDA
5:05 PM
|
MOST: Multi-Stage Optimal Sequential Trial Design for Phase II Clinical Trials with Biomarker Subgroups
Yong Zang, Florida Atlantic University
5:20 PM
|
Comparison of a Targeted Maximum Likelihood Estimator to Other Estimation Techniques for the One-Year Risk of Recurrent MI Among New Users of High vs. Low Potency Statins
Jonathan Todd, The University of North Carolina Gillings School of Global Public Health; Michele Jonsson Funk, The University of North Carolina Gillings School of Global Public Health; Alan Brookhart, The University of North Carolina at Chapel Hill
5:25 PM
|
Monday, 08/10/2015
|
Estimation of Dosage Frequency of Pre-Exposure Prophylaxis Needed to Protect Against HIV Infection
Claire Ruberman
|
Methods for Increasing Power in Vaccine Efficacy Trials
David Benkeser; Peter B. Gilbert, Fred Hutchinson Cancer Research Center; Marco Carone, University of Washington
8:55 AM
|
Subgroup-Based Adaptive (SUBA) Designs for Sequential, Multiple Assignment, Randomized Trials
Yanxun Xu, The University of Texas at Austin; Peter Mueller, The University of Texas at Austin; Peter F. Thall, MD Anderson Cancer Center
11:50 AM
|
Collaborative Targeted Maximum Likelihood Estimator (CTMLE) in Observational Studies
Mark Johannes van der Laan, UC Berkeley; Sam Lendle, UC Berkeley; Sebastian Schneeweiss, Brigham and Women's Hospital
2:25 PM
|
Multistage Adaptive Biomarker-Directed Targeted Clinical Trial Design
Zhong Gao, OBE/CBER/FDA; Ming Tan, Georgetown University; Anindya Roy, University of Maryland, Baltimore County
3:05 PM
|
Tuesday, 08/11/2015
|
Targeted Sampling, Mixed Mode, Incentives, and Paying for Completion: What Works for Reaching Hard-to-Survey Low-Income Households with Civil Legal Needs?
Danna Moore, Washington State University Social & Economic Science Research Center; Arina Gertseva, Social & Economic Sciences Research Center; Nathan Palmer, Social & Economic Sciences Research Center
|
Auto-Adaptive Alpha Allocation: A Strategy to Mitigate Risk on Study Assumptions
Yue Shentu, Merck; Cong Chen, Merck Research Laboratories; Lei Pang, Merck
2:25 PM
|
Thursday, 08/13/2015
|
Bayesian Dose-Finding Designs for Combination of Molecularly Targeted Agents Assuming Partial Stochastic Ordering
Beibei Guo, Louisiana State University; Yisheng Li, MD Anderson Cancer Center
10:55 AM
|
Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy
Rajeshwari Sridhara, FDA
11:15 AM
|
Selection of Multiplicity Adjustment Strategy in Confirmatory Trials with a Targeted Subgroup
Cheng Zheng, Novartis Pharmaceuticals; Zhichao Sun, University of Michigan; Kalyanee Appanna, Novartis Pharmaceuticals; Kaushal Mishra, Novartis Pharmaceuticals; Yong Zhang, Novartis Pharmaceuticals; Feng Tai, Novartis Pharmaceuticals
12:05 PM
|
Keyword "Sequential Mutliple"
Monday, 08/10/2015
|
Set Valued Dynamic Treatment Regimes
Tianshuang Wu, University of Michigan; William Pelham, Florida International University; Susan A. Murphy, University of Michigan
|
|